Proceedings · Session S-394 · filed November 19, 2026

Lab Technology & MethodsSession paper

Exogenus shifts EV batch release to targeted QC assays

Exogenus Therapeutics is using ELISA, Western blot and omics-derived targets to standardize QC for donor-variable umbilical-cord-blood vesicles, while potency assays remain a GMP development gap.

By Tom Whitfield4 min read734 words

Summary

  • Two laboratory techniques anchor Exogenus’ routine EV QC description: ELISA and Western blot.
  • Extracellular vesicles comprise thousands of molecules across five listed classes: lipids, proteins, metabolites, DNA and RNA.
  • Umbilical cord blood carries higher donor variability than conventional EV cell sources, according to Silva.
  • Exogenus uses omics data to select targets for a simpler panel instead of running omics on every release batch.
  • GMP-compatible potency assays still require substantial development for later clinical phases.
Tuning Extracellular Vesicle Production and Analytics for Compliance
FigureTuning Extracellular Vesicle Production and Analytics for Compliance — AI-generated

By Tom Whitfield

Exogenus Therapeutics’ extracellular-vesicle QC workflow names two laboratory techniques—ELISA and Western blot—and draws routine release targets from omics data rather than running omics analysis on every batch.

At Cell & Gene Therapy International Europe, Andreia Silva, PhD, head of research at Exogenus, said the company had converted complicated high-screening analytics into a more sustainable assay panel. Exogenus develops extracellular vesicles derived from umbilical cord blood cells for inflammatory and degenerative conditions.

Her central message was that a non-conventional EV product need not force a heavy manufacturing and QC system. That is a process-development claim, not evidence of clinical efficacy, and the account identifies no candidate, trial, clinical-stage designation or approval timetable.

The account also provides no donor count, batch count, assay-validation results, per-batch cost or external grant; it presents the work as company development. R&D managers can assess the proposed workflow, but the source does not support comparisons of speed, reliability or return on QC spending.

What does the production workflow actually standardize?

Exogenus’ system starts with one of bioprocessing’s harder variables: umbilical cord blood. Silva said this raw material carries a higher level of variability than conventional EV cell sources because it comes from different donors, and the company must turn it into a safe, consistent-quality product.

The product itself resists simplification. Unlike small molecules, extracellular vesicles contain thousands of molecules spanning lipids, proteins, metabolites, DNA and RNA. Silva said those constituents may all be functional when the vesicles reach a target organ, which raises the analytical burden.

Her solution does not put every constituent on every release test. The company uses omics-level molecular data to select specific targets for a simpler routine panel, then applies standardized techniques to product batches. ELISA and Western blot are the two named methods in Silva’s account.

How does omics fit into batch release?

Budget pressure drives that design. Silva said: “We can’t do omics on every single batch of product we are going to release because it would become too expensive down the line. We’ve been looking at the molecular data generated at the omics level and then selecting specific targets to pass that into the simpler QC panel.”

The workflow separates discovery-scale characterization from routine release testing. It may reduce analytical burden, but the source reports no actual cost or turnaround figure, no assay count and no comparison against the company’s earlier process. Nor does it show whether selected targets predict potency.

The panel remains product-specific, so Silva does not present it as a universal EV template. She does expect the general approach—translate complex molecular data into a smaller, standardized test set—to inform other companies developing EVs for the clinic.

What remains before clinical use?

Potency remains the harder gap. Silva said: “Potency assay development for GMP production, so you can use your product in later clinical phases, is still something that needs a lot of development because EVs are such a complex modality.”

That statement draws a line between manufacturing consistency and biological activity. The account reports no validated potency assay, acceptance threshold, correlation with an intended effect or clinical data, leaving Exogenus’ move toward GMP use dependent on further assay work.

Silva expects practical strategies to emerge as companies approach clinical development. For portfolio managers, however, Exogenus’ current position is an assay-design proposal supported by company claims, not a disclosed clinical or manufacturing result.

What should R&D managers ask next?

Before treating the workflow as a benchmark, R&D leaders need answers to five measurable questions:

  • How many donors and production batches establish the observed variability and assay stability? The source supplies neither denominator.
  • Why did the company select each target from omics, and what release attribute does that target measure?
  • What sensitivity, specificity, precision, reproducibility and acceptance criteria did ELISA and Western blot achieve?
  • How much did the redesigned workflow change cost per released batch and laboratory turnaround?
  • Which potency endpoint will connect vesicle activity to the inflammatory or degenerative condition the company seeks to treat?

The next concrete milestone for Exogenus is a validated, GMP-compatible potency assay tied to its intended disease target. Until that result and the underlying batch data appear, the targeted QC panel shows a plausible route to leaner EV manufacturing, not proof that a cord-blood vesicle candidate is clinic-ready.

via Genetic Engineering & Biotechnology News (Source)

Filed under

  • extracellular-vesicles
  • quality-control-assays
  • omics
  • gmp-manufacturing
  • potency-assays
Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Senior reporter covering technology and product news in research and development at Hypothesis Wire.

272 articles

References

  1. Stable Pools Move Biologics Off the Clone-First Path
  2. Evox Builds Potency Assay for Extracellular Vesicle Pipeline
  3. 66% to 90%: The Outsourcing Numbers Driving CGT Contracting
  4. Standardized Apheresis Would Fix Cell Therapy's Variability Problem
  5. Cell Therapy Tech Transfer Is Losing Critical Process Know-How

« Previous article